Article Information
History
- January 9, 2017.
Article Versions
- Version 1 (January 6, 2017 - 15:05).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Julie E. Horowitz1,
- Neil Warner2,3,
- Jeffrey Staples1,
- Eileen Crowley2,3,
- Ryan Murchie2,3,
- Cristopher Van Hout1,
- Alejandra Klauer King1,
- Karoline Fiedler2,3,
- Jeffrey G. Reid1,
- John D. Overton1,
- Alan R. Shuldiner1,
- Aris Baras1,
- Geisinger-Regeneron DiscovEHR Collaboration,
- Frederick E. Dewey1,
- Anne Griffiths2,
- Omri Gottesman1,
- Aleixo M. Muise2,3,4,* and
- Claudia Gonzaga-Jauregui1,*
- 1Regeneron Genetics Center, Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA
- 2SickKids Inflammatory Bowel Disease Center, Hospital for Sick Children, Toronto, ON, Canada
- 3Cell Biology Program, Research Institute, Hospital for Sick Children, Toronto, ON, Canada.
- 4Departments of Pediatrics and Biochemistry, University of Toronto, Toronto, ON, Canada.
- ↵* Corresponding authors, Correspondence should be addressed to: Aleixo Muise MD, Ph.D.
555 University Ave. The Hospital for Sick Children, Toronto, ON, Canada, M5G 1X8, Email: aleixo.muise{at}utoronto.ca, Phone: 416-813-7735, Fax: 416-813-6531, Claudia Gonzaga-Jauregui, Ph.D.
Regeneron Genetics Center, Regeneron Pharmaceuticals Inc. 777 Saw Mill River Rd. Tarrytown, NY, USA, Email: clau.gonzagajauregui{at}regeneron.com, Phone: 914-847-3451